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Abstract The main aim of this study was to investigate
possible associations between measures of offspring size at
birth in the most recent pregnancy before premenopausal
breast cancer diagnosis and the risks of maternal breast
cancer mortality, taking tumor characteristics into account.
We also aimed to investigate if these associations are
modified by age at childbirth, time since childbirth, parity,
and age at diagnosis. We followed 6,019 women from their
date of premenopausal breast cancer (diagnosed from 1992
to 2008) until emigration, death or December 31st, 2009,
whichever occurred first. We used Cox proportional hazard
regression models, adjusted for parity, age at diagnosis, and
education level, to estimate associations between women
pregnancy, cancer characteristics and offspring birth
characteristics, and mothers’ mortality risk. In stratified
analyses, mortality risks were estimated by tumor stage,
ER or PR status. There was no association between off-
spring birth weight (HR = 1.00, 95 % CI 0.99–1.01, when
used as a continuous variable), birth weight for gestational
age or ponderal index, and premenopausal breast cancer
mortality. Similarly, in analyses stratified by tumor stage,
receptor status, and time difference between last pregnancy
and date of diagnosis, we found no associations between
birth size and breast cancer mortality. Our findings suggest
that the hypothesis that ‘‘premenopausal breast cancer
mortality is associated with offspring birth characteristics
in the most recent pregnancy before the diagnosis’’ may not
be valid. In addition, these associations are not modified by
tumor characteristics.
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Introduction
Estrogens are well-established risk factors for breast cancer
[25, 30] and may also influence breast cancer prognosis.
Mortality rates are higher among women diagnosed with
breast cancer up to 10 years following delivery, and the
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prognosis is especially poor in women with breast cancer
diagnosed during or shortly after pregnancy [2, 4, 12, 15,
21, 23, 31, 32]. Although underlying mechanisms remain
unknown, hormonal factors may play a role.
During pregnancy, there is a large increase in hormone
production, which is primarily produced by the placenta.
Estrogen levels increase with placental weight, which may
serve as an indirect marker of pregnancy hormone expo-
sures. In a Swedish study, Larfors et al. [16] showed that
increasing placental weight in the most recent pregnancy
before breast cancer diagnosis was associated with reduced
breast cancer survival. We recently reported that the
association between high placental weight and premeno-
pausal breast cancer mortality was modified by tumor
characteristics: the risk was most pronounced among
estrogen receptor (ER) negative and progesterone receptor
(PR) negative tumors [8].
A positive association between birth weight and level of
pregnancy hormones, particularly estrogens, has also been
documented [10, 13, 22, 28]. Kaijser et al. [13] found that
maternal serum estriol levels increased with offspring birth
weight, birth weight for gestational age (a proxy for fetal
growth), and ponderal index, i.e., the ratio of birth weight
and birth length [100 * birth weight (in grams) divided by
birth length (in centimetres3)]. Thus, offspring birth
weight, birth weight for gestational age, and ponderal index
can also be considered as indirect markers of exposure to
hormone levels during pregnancy [13].
A Finnish study, including 3,706 women with repro-
ductive history of which 190 women were later diagnosed
with breast cancer, found a statistically significant positive
association between ponderal index and risk of breast
cancer mortality [27]. However, there was no association
between offspring birth weight and breast cancer mortality
[26, 27]. To the best of our knowledge, no study to date has
examined the association between offspring birth charac-
teristics and breast cancer mortality, taking tumor charac-
teristics into account.
In this large population-based cohort study, we investi-
gated possible associations between measures of offspring
size at birth in the most recent pregnancy before pre-
menopausal breast cancer diagnosis and the risks of
maternal breast cancer mortality, taking tumor character-
istics into account. We also investigated if these associa-
tions are modified by age at childbirth, time since
childbirth, parity, and age at diagnosis.
Materials and methods
The six Swedish Regional Quality Registers capture more
than 95 % of the incident breast cancer cases and include
data on diagnostic procedures and treatments [3]. In these
registries, information on tumor stage and biological
characteristics at diagnosis, including grade and hormone
(estrogen or progesterone) receptor status, has been col-
lected since 1992. Women who received a diagnosis of
premenopausal breast cancer between 1992 and 2008 were
identified through two Swedish Regional Quality Registers
on Breast Cancer covering the Stockholm-Gotland Region
and Central Sweden. These registries included self-repor-
ted information about menopausal status.
Women with a recorded pregnancy before diagnosis of
premenopausal breast cancer were identified through
record linkage to the Swedish Medical Birth Register
(n = 6,129). The Medical Birth Register includes pro-
spectively collected information during pregnancy, deliv-
ery, and the neonatal period on virtually all births in
Sweden since 1973. Information about vital status and
dates of emigration was retrieved from the Swedish Pop-
ulation Register. Highest achieved educational level was
obtained from the Education Register. The Cause of Death
Register provided information on main and contributing
causes of death, coded according to International Classifi-
cation of Diseases, 7th–10th versions (ICD-7–ICD-10).
The unique personal identity number, assigned to each
Swedish resident, was used to link individual records
across these registries [18].
We excluded 41 women due to missing information on
birth weight or gestational age. Women with pregnancies
that ended in stillbirth (n = 18) and twin pregnancies
(n = 51) were also excluded. In total, the cohort included
6,019 women with premenopausal breast cancer. As breast
cancer was recorded as the main or contributory cause of
death for approximately 99 % of the events, death due to
all causes was used as the outcome.
The study was approved by the Research Ethics Com-
mittee of Karolinska Institutet.
Statistical analysis
We used Cox proportional hazards model to estimate
hazard ratios (HR) with 95 % confidence intervals (CI) as a
measure of the association between birth characteristics
and risk of premenopausal breast cancer mortality. Follow-
up was from the date of diagnosis of breast cancer until
emigration, death or until December 31st, 2009, whichever
occurred first. Follow-up time was the underlying time
scale.
Birth weight was considered as a continuous and a
categorical variable (\3000, 3000–3499, 3500–3999,
4000–4499, and C4500 g). We also estimated associations
between birth weight for gestational age and ponderal
index and breast cancer mortality. Birth weight for gesta-
tional age was estimated using the Swedish reference curve
for normal fetal growth and was defined as the ratio of
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observed to expected birth weight for gestational age and
sex. Birth weight for gestational age was categorized in
percentiles (\3, 3–\10, 10–90, 91–97, and [97 %) [19].
As infants within the 10–90 % are considered as being
‘‘appropriate for gestational age’’, this category was used as
the reference group [5, 24]. The association was estimated
using birth weight for gestational age as a continuous and a
categorized variable. We also evaluated the quadratic term
for potential non-linear associations between offspring
birth characteristics and breast cancer mortality. Ponderal
index was categorized in percentile ranges equivalent to the
categorization of birth weight for gestational age (\3,
3–\10, 10–90, 91–97, and [97 %). All the models were
adjusted for parity (1, 2, 3, and C4), gestational age (B36,
Table 1 Offspring birth characteristics, hazard ratios (HR), and 95 % confidence interval (CI) for breast cancer mortality. Parous women with
premenopausal breast cancer diagnosed 1992–2009 in Sweden
Subject Event Crude HR (95 % CI) Adjusted HR (95 % CI)a
Birth weight (gram)
\3,000 783 132 1.07 (0.88–1.31) 1.12 (0.90–1.40)
3,000–3,499 1,862 330 1.12 (0.96–1.30) 1.13 (0.97–1.32)
3,500–3,999 2,162 337 Referent Referent
4,000–4,499 971 181 1.18 (0.99–1.41) 1.16 (0.97–1.40)
C4,500 241 37 1.04 (0.74–1.45) 1.06 (0.75–1.49)
P for trend 0.42 0.42
Continuous (100 g) 6,019 1,017 1.00 (0.99–1.01) 1.00 (0.99–1.01)
Birth length (cm)
\49 1,053 181 1.10 (0.92–1.31) 1.14 (0.94–1.38)
49 751 137 1.18 (0.97–1.44) 1.19 (0.98–1.45)
50–51 2,292 365 Referent Referent
C52 1,890 334 1.11 (0.95–1.28) 1.10 (0.95–1.28)
Continuous (cm) 5,988 1,017 1.00 (0.98–1.03) 1.00 (0.97–1.02)
Missing 31 0
Gestational age (weeks)
B36 305 42 0.78 (0.57–1.06) 0.74 (0.54–1.01)
37–38 1,070 167 0.95 (0.80–1.12) 0.94 (0.80–1.12)
39–41 4,140 704 Referent Referent
C42 504 104 1.15 (0.94–1.42) 1.12 (0.91–1.37)
Continuous (week) 6,019 1,017 1.04 (1.00–1.07) 1.03 (1.00–1.07)
Birth weight for gestational age (%)
\3 132 33 1.52 (1.07–2.15) 1.55 (1.09–2.21)
3–\10 294 60 1.15 (0.89–1.50) 1.09 (0.84-1.42)
10–90 4,865 801 Referent Referent
91–97 493 88 1.08 (0.87–1.35) 1.12 (0.90–1.39)
[97 231 35 1.00 (0.71–1.40) 1.05 (0.75–1.48)
Continuous 6,015 1,017 0.97 (0.91–1.02) 0.99 (0.93–1.04)
Missing 4 0
Ponderal index (%)
\3 174 36 1.17 (0.84–1.64) 1.25 (0.89–1.77)
3–\10 410 85 1.24 (0.99–1.55) 1.24 (0.99–1.56)
10–90 4,802 799 Referent Referent
91–97 420 75 1.16 (0.91–1.47) 1.18 (0.93–1.49)
[97 182 22 0.77 (0.51–1.18) 0.78 (0.51–1.19)
Continuous 5,988 1,017 1.01 (0.85–1.20) 1.00 (0.84–1.19)
Missing 31 0
a Adjusted for gestational age, parity, and educational level
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Table 2 Pregnancy factors, tumor characteristics, and hazard ratios (HR) with 95 % confidence interval (CI) for breast cancer mortality. Parous
women with premenopausal breast cancer diagnosed 1992–2009 in Sweden
Subjects Events HR (95 % CI) Adjusted HR (95 % CI)a
Pregnancy factors
Parity
1 1,250 234 Referent Referent
2 3,048 504 0.88 (0.75–1.03) 0.88 (0.76–1.03)
3 1,307 201 0.78 (0.65–0.94) 0.82 (0.68–0.99)
C4 414 78 0.96 (0.74–1.24) 0.99 (0.76–1.28)
Preeclampsia
Yes 48 7 0.93 (0.44–1.94) 1.01 (0.48–2.12)
No 5,971 1,010 Referent Referent
Education level
Below high school 733 174 Referent Referent
High school 2,695 487 0.83 (0.69–0.98) 0.78 (0.65–0.92)
Above high school 2,584 353 0.61 (0.51–0.73) 0.60 (0.50–0.72)
Missing 7 3
Age at breast cancer diagnosis (years)
\30 60 21 3.24 (2.04–5.13) 3.00 (1.89–4.78)
30–34 298 85 2.63 (2.00–3.45) 2.61 (1.98–3.24)
35–39 815 167 1.77 (1.41–2.22) 1.76 (1.40–2.22)
40–44 1,576 290 1.48 (1.21–1.82) 1.49 (1.21–1.82)
45–49 2,129 321 1.19 (0.97–1.45) 1.78 (0.96–1.44)
50–54 1,141 133 Referent Referent
Continuous (year) 6,019 1,017 0.95 (0.94–0.96) 0.95 (0.94–0.96)
Time between last pregnancy and breast cancer diagnosis (years)
\5 839 196 1.77 (1.50–2.08) 1.36 (1.09–1.69)
5–9 1,168 228 1.34 (1.15–1.56) 1.22 (1.03–1.46)
C10 4,012 593 Referent Referent
Continuous (year) 6,019 1,017 0.88 (0.84–0.93) 0.98 (0.91–1.05)
Tumor characteristics
Stage of tumor
Stage 0–1 3,018 288 Referent Referent
Stage 2 1,852 355 2.15 (1.84–2.52) 2.06 (1.76–2.40)
Stage 3 275 109 5.53 (4.43–6.89) 4.96 (3.97–9.20)
Stage 4 77 49 12.93 (9.54–17.53) 12.22 (8.99–16.60)
Unkown 797 216 2.13 (1.78–2.55) 2.03 (1.70–2.43)
ER status
Positive 3,821 450 Referent Referent
Negative 1,246 316 2.15 (1.86–2.48) 1.90 (1.64–2.20)
Unknown 952 251 1.69 (1.45–1.97) 1.43 (1.22–1.68)
PR status
Positive 3,611 430 Referent Referent
Negative 1,421 336 2.30 (1.99–2.65) 1.95 (1.68–2.25)
Unknown 987 251 1.67 (1.43–1.96) 1.41 (1.20–1.66)
ER/PR status
ER?/PR? 3,348 364 Referent Referent
ER?/PR- 433 82 2.14 (1.68–2.72) 1.79 (1.41–2.29)
ER-/PR? 256 63 1.80 (1.38–2.35) 1.72 (1.32–2.25)
ER-/PR- 986 253 2.59 (2.21–3.04) 2.19 (1.86–2.58)
Unknown 996 255 1.82 (1.55–2.14) 1.53 (1.29–1.80)
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37–38, 39–41, and C42 weeks), and education level (less
than high school, high school, and above high school).
We estimated the association between birth weight for
gestational age and maternal mortality among different
subgroups. In stratified analyses, we estimated the risk of
mortality in subjects with different tumor stages (stage 0–1,
stage 2, stage 3 or stage 4), estrogen receptor status (ER?,
ER-), progesterone receptor status (PR?, PR-), joint
receptor status (ER?PR?, ER-PR?, ER?PR-, ER-PR-),
and histology of tumors (ductal, lobular, other). The
models were adjusted for parity, gestational age, education
level, and age at cancer diagnosis (\30, 30–34, 35–39,
40–44, 45–49, and 50–54 years).
The assumption of proportionality was verified for all
models, by including time-by covariate interaction in the
model and testing the statistical significance. As a basis for
the linear trend tests across categories of offspring birth
characteristics, each subject was assigned the median value
of the specific category, and this variable was treated as a
continuous variable in modeling. All analyses were per-
formed using the SAS software version 9.3 (SAS Institute,
Cary, NC, USA).
Results
Table 1 shows offspring birth characteristics and crude and
adjusted maternal mortality risks of breast cancer. We
found no statistically significant association between off-
spring birth weight and maternal mortality of breast cancer,
neither when birth weight was used as a continuous (1.00,
95 % CI 0.99–1.01) nor as a categorical variable (P for
trend 0.42). Compared to women who had an infant with
normal birth weight for gestational age (between 10th and
90th percentiles), women with a small for gestational age
infant (\3rd percentile) in the most recent pregnancy had
an increased mortality risk (HR = 1.55, 95 % CI
1.09–2.21). We found no associations between ponderal
index and maternal mortality of premenopausal breast
cancer, neither when ponderal index was used as a con-
tinuous variable nor when used as a categorical variable
(Table 1). In analyses of quadratic term for offspring birth
characteristics, we found no statistically significant non-
linear associations with the higher-order term of breast
cancer mortality, other than a risk associated with birth
weight for gestational age (1.04, 95 % CI 1.01–1.07).
Table 2 shows crude and adjusted hazard ratios for preg-
nancy factors or tumor characteristics and maternal mortality
of premenopausal breast cancer. Risk of premenopausal breast
cancer mortality was inversely associated with increasing age
at diagnosis, educational level, and time between pregnancy
and diagnosis of the cancer. Analysis by tumor characteristics
showed that premenopausal breast cancer mortality was pos-
itively associated with tumor stage, ER negative, and PR
negative tumors. Analysis by joint receptor status revealed
that women with ER and PR negative tumors had the highest
premenopausal breast cancer mortality (Table 2). Restricting
data to women who were born in Nordic countries (i.e.,
Sweden, Denmark, Finland, Iceland, and Norway) did not
change the results (data not shown).
The association between offspring birth weight for ges-
tational age and premenopausal breast cancer mortality
stratified by tumor characteristics is shown in Table 3.
Stratified analyses revealed that the observed increased
mortality risk for the lowest category of birth weight for
gestational age was present in those with cancer diagnosed
5–9 years after the pregnancy, in women who were 40 years
or younger at the time of diagnosis, in women diagnosed with
stage 2 tumors, and in women with ER positive tumors.
Analysis stratified by parity showed that birth weight for
gestational age (as a continuous variable) had statistically
significant inverse association with mortality of premeno-
pausal breast cancer among uniparous women (HR = 0.87,
95 % CI 0.78–0.98), but not in multiparous women
(HR = 1.01, 95 % CI 0.94–1.08). Thus, the increased risk
of breast cancer mortality related to birth of a small for
gestational age infant before breast cancer diagnosis
appeared to be restricted to primiparous women.
Discussion
This population-based cohort study found no association
between birth weight, as an indirect marker of perinatal
Table 2 continued
Subjects Events HR (95 % CI) Adjusted HR (95 % CI)a
Histological type
Ductal 4,143 652 Referent Referent
Lobular 640 103 0.94 (0.76–1.15) 0.95 (0.77–1.17)
Other 820 153 1.00 (0.84–1.19) 0.97 (0.81–1.16)
Unknown 416 109 1.10 (0.90–1.36) 1.09(0.88–1.35)
a Adjusted for gestational age, parity, age at diagnosis, and educational level
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Table 3 Stratified analyses of offspring birth weight for gestational age (in %) and hazard ratio (HR) and 95 % confidence interval (CI) for
mother’s premenopausal breast cancer mortality
Subject Event Crude HR (95 % CI) Adjusted HR (95 % CI)a
Birth weight for gestational age (%)
\3 132 33 1.52 (1.07–2.15) 1.55 (1.09–2.21)
3–\10 294 60 1.15 (0.89–1.50) 1.09 (0.84–1.42)
10–90 4,865 801 Referent Referent
91–97 493 88 1.08 (0.87–1.35) 1.11 (0.90–1.39)
[97 231 35 1.00 (0.71–1.40) 1.05 (0.75–1.48)
Continuous 6,015 1,017 0.97 (0.91–1.02) 0.99 (0.93–1.04)
Quadratic 1.03 (1.00–1.06) 1.04 (1.01–1.07)
Time difference between last pregnancy and date of diagnosis
\5 years
\3 14 5 1.49 (0.61–3.64) 1.78 (0.72–4.39)
3–\10 31 8 1.03 (0.51–2.09) 1.21 (0.59–2.49)
10–90 675 155 Referent Referent
91–97 83 16 0.85 (0.51–1.41) 0.88 (0.52–1.47)
[97 35 12 1.86 (1.03–3.35) 1.95 (1.08–3.53)
Continuous 838 196 1.00 (0.88–1.15) 0.99 (0.86–1.13)
5–9 years
\3 23 9 2.04 (1.04–3.99) 2.21 (1.11–4.40)
3–\10 48 13 1.53 (0.87–2.70) 1.53 (0.84–2.76)
10–90 942 175 Referent Referent
91–97 102 24 1.27 (0.83–1.94) 1.25 (0.81–1.91)
[97 52 7 0.78 (0.36–1.65) 0.90 (0.42–1.94)
Continuous 1,167 228 0.94 (0.83–1.06) 0.95 (0.84–1.07)
C10 years
\3 95 19 1.41 (0.89–2.23) 1.30 (0.81–2.08)
3–\10 215 39 1.15 (0.83–1.59) 1.06 (0.76–1.48)
10–90 3,248 471 Referent Referent
91–97 308 48 1.06 (0.79–1.43) 1.08 (0.80–1.45)
[97 144 16 0.80 (0.49–1.31) 0.88 (0.53–1.45)
Continuous 4,010 593 0.94 (0.88–1.02) 0.97 (0.90–1.05)
Age at diagnosis
B40 years
\3 66 20 1.55 (0.99–2.42) 1.72 (1.09–2.72)
3–\10 150 38 1.25 (0.90–1.74) 1.27 (0.90–1.78)
10–90 2,560 493 Referent Referent
91–97 282 56 1.02 (0.77–1.34) 1.03 (0.78–1.36)
[97 119 23 1.13 (0.75–1.72) 1.19 (0.78–1.81)
Continuous 3,177 630 0.90 (0.91–1.04) 0.97 (0.90–1.04)
[40 years
\3 66 13 1.51 (0.87–2.63) 1.41 (0.82–2.52)
3–\10 144 22 1.03 (0.67–1.59) 0.95 (0.61–1.46)
10–90 2,305 308 Referent Referent
91–97 211 32 1.15 (0.80–1.65) 1.21 (0.84–1.74)
[97 112 12 0.83 (0.47–1.48) 0.90 (0.51–1.61)
Continuous 2,838 387 0.94 (0.85–1.03) 0.97 (0.88–1.07)
Tumor stage
Stage 0–1
\3 61 6 1.03 (0.46–2.32) 1.11 (0.49–2.54)
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Table 3 continued
Subject Event Crude HR (95 % CI) Adjusted HR (95 % CI)a
3–\10 159 21 1.29 (0.83–2.02) 1.19 (0.75–1.89)
10–90 2,460 225 Referent Referent
91–97 226 29 1.46 (0.99–2.15) 1.46 (0.99–2.16)
[97 110 7 0.74 (0.35–1.56) 0.89 (0.42–1.89)
Continuous 3,016 288 1.01 (0.90–1.12) 1.01 (0.91–1.13)
Stage 2
\3 43 17 2.04 (1.25–3.33) 2.19 (1.32–3.62)
3–\10 74 19 1.30 (0.82–2.07) 1.35 (0.84–2.17)
10–90 1,502 282 Referent Referent
91–97 159 25 0.81 (0.54–1.22) 0.77 (0.51–1.17)
[97 74 12 0.95 (0.53–1.69) 0.96 (0.54–1.71)
Continuous 1,852 355 0.87 (0.79–0.96) 0.87 (0.79–0.96)
Stage 3–4
\3 11 5 1.05 (0.43–2.56) 1.05 (0.42–2.61)
3–\10 23 11 1.16 (0.62–2.15) 1.10 (0.58–2.11)
10–90 267 120 Referent Referent
91–97 31 15 1.21 (0.71–2.08) 1.09 (0.63–1.92)
[97 19 7 0.97 (0.45–2.07) 1.00 (0.44–2.28)
Continuous 351 158 1.02 (0.89–1.17) 1.04 (0.90–1.20)
Receptor status
ER?
\3 76 16 1.87 (1.13–3.08) 1.86 (1.11–3.12)
3–\10 182 26 1.10 (0.74–1.64) 1.10 (0.74–1.65)
10–90 3,106 353 Referent Referent
91–97 296 38 1.13 (0.81–1.58) 1.10 (0.78–1.54)
[97 157 17 1.03 (0.64–1.68) 1.11 (0.68–1.81)
Continuous 3,817 450 0.97 (0.89–1.06) 0.97 (0.89–1.06)
ER-
\3 25 9 1.44 (0.74–2.80) 1.48 (0.75–2.90)
3–\10 65 17 1.02 (0.62–1.66) 1.02 (0.62–1.68)
10–90 996 253 Referent Referent
91–97 117 30 1.08 (0.74–1.57) 1.13 (0.77–1.65)
[97 43 7 0.62 (0.29–1.31) 0.70 (0.33–1.50)
Continuous 1,246 316 0.94 (0.85–1.05) 0.97 (0.87–1.08)
PR?
\3 64 12 1.62 (0.91–2.88) 1.67 (0.93–3.01)
3–\10 179 25 1.07 (0.71–1.60) 1.05 (0.70–1.59)
10–90 2,953 343 Referent Referent
91–97 275 36 1.10 (0.78–1.54) 1.06 (0.75–1.50)
[97 136 14 0.96 (0.56–1.64) 1.05 (0.61–1.80)
Continuous 3,607 430 0.97 (0.89–1.06) 0.98 (0.89–1.07)
PR-
\3 34 13 1.66 (0.95–2.90) 1.69 (0.96–2.99)
3–\10 66 17 1.05 (0.64–1.71) 1.07 (0.65–1.76)
10–90 1,121 265 Referent Referent
91–97 136 31 1.03 (0.71–1.50) 1.04 (0.72–1.52)
[97 64 10 0.66 (0.35–1.23) 0.71 (0.37–1.33)
Continuous 1,421 336 0.93 (0.85–1.03) 0.95 (0.86–1.05)
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Table 3 continued
Subject Event Crude HR (95 % CI) Adjusted HR (95 % CI)a
Joint receptor status
ER?PR?
\3 61 11 1.73 (0.95–3.16) 1.77 (0.95–3.29)
3–\10 168 23 1.15 (0.75–1.76) 1.16 (0.75–1.78)
10–90 2,728 285 Referent Referent
91–97 254 31 1.14 (0.79–1.65) 1.10 (0.76–1.60)
[97 133 14 1.07 (0.63–1.83) 1.18 (0.69–2.02)
Continuous 3,344 364 0.98 (0.89–1.08) 0.98 (0.89–1.09)
ER?PR-
\3 12 5 2.41 (0.97–5.98) 2.61 (0.97–7.05)
3–\10 12 2 0.75 (0.18–3.07) 0.44 (0.06–3.30)
10–90 345 66 Referent Referent
91–97 40 6 0.86 (0.37–1.98) 0.88 (0.38–2.06)
[97 24 3 0.74 (0.23–2.37) 0.77 (0.24–2.50)
Continuous 433 82 0.93 (0.76–1.12) 0.92 (0.75–1.11)
ER-PR?
\3 3 1 1.20 (0.17–8.64) 1.25 (0.16–9.95)
3–\10 11 2 0.64 (0.16–2.62) 0.64 (0.15–2.74)
10–90 218 55 Referent Referent
91–97 21 5 0.89 (0.35–2.22) 0.96 (0.37–2.49)
[97 3 0 0.00 0.00
Continuous 256 63 0.98 (0.76–1.28) 1.00 (0.76–1.31)
ER-PR-
\3 22 8 1.42 (0.70–2.89) 1.50 (0.72–3.08)
3–\10 54 15 1.08 (0.64–1.83) 1.13 (0.66–1.92)
10–90 774 198 Referent Referent
91–97 96 25 1.09 (0.72–1.65) 1.15 (0.75–1.75)
[97 40 7 0.63 (0.30–1.34) 0.74 (0.34–1.58)
Continuous 986 253 0.93 (0.83–1.04) 0.96 (0.85–1.07)
Parity
Uniparous
\3 47 13 1.61 (0.92–2.83) 1.72 (0.96–3.11)
3–\10 100 27 1.49 (0.99–2.23) 1.42 (0.93–2.16)
10–90 993 174 Referent Referent
91–97 81 16 1.14 (0.68–1.91) 1.12 (0.67–1.87)
[97 28 4 0.88 (0.33–2.36) 0.87 (0.32–2.36)
Continuous 1,249 234 0.89 (0.79–1.00) 0.87 (0.78–0.98)
Multiparous
\3 85 20 1.44 (0.92–2.24) 1.51 (0.96–2.37)
3–\10 194 33 0.95 (0.67–1.36) 0.99 (0.70–1.41)
10–90 3,872 627 Referent Referent
91–97 412 72 1.08 (0.84–1.37) 1.07 (0.84–1.36)
[97 203 31 1.02 (0.71–1.47) 1.09 (0.76–1.57)
Continuous 4,766 783 1.00 (0.94–1.07) 1.01 (0.94–1.08)
a Adjusted for parity, gestational age, age at diagnosis, and education level
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hormonal exposure, and maternal premenopausal breast
cancer mortality. These null findings also remained in
analyses stratified by tumor characteristics, including time
between pregnancy and breast cancer diagnosis, tumor
stage, and receptor expression status. There was an inverse
association between birth weight for gestational age and
mortality of premenopausal breast cancer among uniparous
women.
We are unaware of any study investigating the associ-
ation between offspring birth size and maternal breast
cancer mortality risk, taking tumor characteristics into
account. The results of the present study are not consistent
with the findings of our recent study [8] in which we found
an increased mortality risk in premenopausal breast cancer
associated with higher placental weight in the most recent
pregnancy. The reported effect modification by tumor
characteristics in our previous study [8]—the risk was most
pronounced among estrogen receptor (ER) negative and
progesterone receptor (PR) negative tumors—was not
present in this study. As the placenta is the main source of
pregnancy hormones, placental weight might be a more
robust and independent marker of hormone exposures
during pregnancy than birth weight [29], which may
explain the inconsistency between the two studies. In a
study examining the association between reproductive
factors and risk of premenopausal breast cancer [6], the
effect of birth weight disappeared after adjusting for pla-
cental weight. Moreover, placental weight or birth weight
could be markers of other exposure(s) which could affect
breast cancer mortality. For example, disproportionately
large placentas could reflect a chronic process requiring
placental overgrowth, such as maternal anemia or malnu-
trition [17], but whether such factors influence breast
cancer mortality remain highly speculative.
Unexpectedly, we found increased maternal mortality
risk among women giving birth to small for gestational age
offspring. The increased risk was restricted to uniparous
women when we considered the association in subcatego-
ries of parity. Although the mechanism of these unexpected
associations is not clear, it is conceivable that it might be
due to comorbidities in the mother—such as autoimmune
diseases [7, 20]—or other risk factors such as cigarette
smoking [14], which could affect both offspring birth
weight and mortality. However, we cannot rule out that
these findings are due to chance.
Strengths of this study include the large sample size and
population-based design including virtually all women in
Central Sweden diagnosed with premenopausal breast
cancer during the study period. Moreover, as we used
prospectively recorded information about pregnancy char-
acteristics and detailed information on tumor characteris-
tics retrieved from separate data sources, recall bias is not
an issue. The Breast Cancer Quality Register provided high
quality and virtually complete information on stage and
characteristics of tumor at diagnosis, including grade and
hormone (estrogen or progesterone) receptor status [9]. The
population covered in this study is approximately 4 million
living in both urban and rural areas, and is likely to be
representative of the whole Swedish population.
This study has some limitations. We used birth weight,
birth weight for gestational age, and ponderal index as
indirect markers of pregnancy hormonal exposure. These
factors could also represent markers of other exposures
which might be associated with breast cancer mortality or
modify the association under investigation. Another limi-
tation is that we did not always have detailed information
on the first pregnancy which is suggested as an important
factor to control for [11]. Furthermore, gestational age was
estimated based on the first day of last menstruation
(LMP), an estimation prone to misclassification due to
possible incorrect recall [1, 33].
In conclusion, our findings suggest that the hypothesis
that ‘‘premenopausal breast cancer mortality is associated
with offspring birth characteristics in the most recent
pregnancy before the diagnosis’’ may not be valid. In
addition, these associations are not modified by tumor
characteristics.
Part of the results is presented in the European Congress
of Epidemiology, Aarhus, Denmark, 2013.
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